Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Nicholas

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Translational Psychiatry|September 12, 2024
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experienceChristopher R Nicholas, Matthew I Banks, Richard C Lennertz, et al.
Brain : a Journal of Neurology|June 22, 2016
Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlifeAnnie M Racine, Rebecca L Koscik, Sara E Berman, et al.
Journal of Alzheimer'S Disease : JAD|September 3, 2016
Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's DiseaseAnnie M Racine, Lindsay R Clark, Sara E Berman, et al.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|May 20, 2016
Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative DataLindsay R Clark, Rebecca L Koscik, Christopher R Nicholas, et al.
Brain Imaging and Behavior|June 11, 2017
Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adultsAnnie M Racine, Andrew P Merluzzi, Nagesh Adluru, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 26, 2016
Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention studyLindsay R Clark, Annie M Racine, Rebecca L Koscik, et al.
Nature Medicine|October 7, 2024
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
Nature Medicine|September 14, 2023
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 9, 2016
Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulationAnnie M Racine, Rebecca L Koscik, Christopher R Nicholas, et al.
JAMA|August 31, 2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical TrialCharles L Raison, Gerard Sanacora, Joshua Woolley, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Translational Psychiatry|September 12, 2024
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experienceChristopher R Nicholas, Matthew I Banks, Richard C Lennertz, et al.
Brain : a Journal of Neurology|June 22, 2016
Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlifeAnnie M Racine, Rebecca L Koscik, Sara E Berman, et al.
Journal of Alzheimer'S Disease : JAD|September 3, 2016
Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's DiseaseAnnie M Racine, Lindsay R Clark, Sara E Berman, et al.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|May 20, 2016
Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative DataLindsay R Clark, Rebecca L Koscik, Christopher R Nicholas, et al.
Brain Imaging and Behavior|June 11, 2017
Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adultsAnnie M Racine, Andrew P Merluzzi, Nagesh Adluru, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 26, 2016
Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention studyLindsay R Clark, Annie M Racine, Rebecca L Koscik, et al.
Nature Medicine|October 7, 2024
Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
Nature Medicine|September 14, 2023
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 9, 2016
Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulationAnnie M Racine, Rebecca L Koscik, Christopher R Nicholas, et al.
JAMA|August 31, 2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical TrialCharles L Raison, Gerard Sanacora, Joshua Woolley, et al.
Pageof 4